Core Viewpoint - The document outlines the compensation management system for the board of directors and senior management of Lushang Furuida Pharmaceutical Co., Ltd, aiming to enhance governance and establish effective incentive and restraint mechanisms [1] Group 1: General Principles - The compensation system is designed to motivate directors and senior management by linking their pay to the company's long-term interests, scale, performance, and individual contributions [3][4] - The system emphasizes a balance between incentives and constraints, ensuring that compensation reflects both company performance and individual responsibilities [3] Group 2: Management Structure - The Compensation and Assessment Committee of the board is responsible for evaluating directors and senior management, setting assessment standards, and determining compensation policies [2][3] Group 3: Compensation and Assessment Management - Independent directors receive a fixed monthly allowance approved by the shareholders' meeting, while non-independent directors receive compensation based on their roles without additional allowances [2][3] - Senior management's compensation consists of a fixed salary and performance-based pay, with the latter determined by annual operational goals and individual performance [2][3] Group 4: Compensation Adjustment - The compensation system is adaptable to align with the company's development strategy and can be adjusted in response to significant changes in the operating environment [6] - Special rewards or penalties can be established for specific matters, subject to approval by the Compensation and Assessment Committee and the board [6] Group 5: Implementation and Compliance - The compensation management system will be executed in accordance with national laws and regulations, and the board is responsible for its interpretation and revision [7]

Group 1 - The company aims to enhance its governance mechanism and strengthen internal control by establishing a system for independent directors to supervise information disclosure [1] - Independent directors are required to diligently fulfill their responsibilities during the preparation and disclosure of the annual report, ensuring the report is true, accurate, and complete [1][2] - The management must provide a comprehensive report on the company's operational status and significant matters to independent directors at the end of each fiscal year [2] Group 2 - Independent directors are responsible for verifying the qualifications of the accounting firm and the registered accountants involved in the annual audit [2] - The company’s financial officer must submit the annual audit plan and relevant materials to independent directors before the audit begins [2] - There should be necessary communication between independent directors and the registered accountants, including a meeting to discuss audit findings before the board meeting [2][3] Group 3 - The company’s secretary is responsible for facilitating communication between independent directors and the management team during the annual report preparation [3] - This working system will take effect after being approved by the company's board of directors [3] - Any matters not covered by this system will be executed according to national laws and regulations, and the company’s articles of association [3]

公司依据法律法规的要求应当报送的，需要将报送的外部单位相关人员作为内 幕知情人备案。公司应将报送的相关信息作为内幕信息，并书面提醒报送的外部单 位及相关人员履行保密义务，不得泄漏依据法律法规报送的本公司未公开重大信息， 不得利用所获取的未公开重大信息买卖本公司证券或建议他人买卖本公司证券。 第七条 公司依照统计、税收征管等法律法规的规定向政府有关部门或其他外部 单位报送公司尚未公开的重大信息（含经营财务数据等）的，或公司在进行申请授 信、贷款、融资、商务谈判等事项时因特殊情况确实需要向对方提供公司的尚未公 开重大信息的，需将报送的外部单位相关人员作为内幕信息知情人登记在案备查。 第八条 公司对外信息报送人员应当书面告知外部单位及其工作人员，因保密不 当致使前述重大信息被泄露时，应立即通知公司，公司应在知悉后的第一时间向上 海证券交易所报告并公告。 第一条 为加强公司定期报告及重大事项在编制、审议和披露期间的外部信息使 用人管理，依据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券 交易所股票上市规则》等法律、法规、规范性文件及《鲁商福瑞达医药股份有限公 司章程》（以下简称"公司章程"）等有关规定，制 ...

第一条 为进一步强化鲁商福瑞达医药股份有限公司（以下简称"公司"）董事会审 计委员会监督职能，保障审计委员会委员切实履行勤勉尽责的义务，充分发挥审计委员会 在年报编制和披露方面的监督作用，根据中国证券监督管理委员会、上海证券交易所的有 关法律法规和《鲁商福瑞达医药股份有限公司章程》（以下简称"公司章程"）、《鲁商 福瑞达医药股份有限公司董事会专门委员会实施细则》及其他有关规定，制定本工作规程。 第二条 审计委员会在公司年度报告的编制和披露过程中，应当认真履行职责，勤勉 尽责。 第三条 在年度报告编制和审议期间，审计委员会委员负有保密义务。在年度报告披 露前，严防泄露内幕信息、内幕交易等违法违规行为发生。 第十二条 本工作规程由董事会负责制定并解释，并自董事会审议通过后实施，未尽 事宜依照有关法律、法规、规范性文件及公司章程的有关规定执行。 鲁商福瑞达医药股份有限公司董事会 第七条 审计委员会在年审外聘审计师进场后保持与外聘审计师的沟通，在外聘审计 师出具审计报告草稿后通过临时会议或传阅资料的方式再一次审阅公司财务会计报表，审 查外聘审计师是否独立客观及审计程序是否有效，形成书面意见。 第八条 公司年度财务会计 ...

第一章 总则 《鲁商福瑞达医药股份 有限公司章程》（以下简称"公司章程"）等有关规定，制定本制度。 第二条 内部审计是指公司内部机构或人员，对公司内部控制和风险管理的 有效性、财务信息的真实性和完整性以及经营活动的效率和效果等开展的一种评 价活动。它通过系统、规范的方法，审查、评价公司各级组织经营活动及目标实 现、内部控制建立执行、资源利用等情况。 第三条 内部审计的目的是促进公司依法经营、规范管理、提高效益，增强 风险防控能力。 第一条 为加强鲁商福瑞达医药股份有限公司（以下简称"公司"）内部管 理和审计监督，维护公司合法权益，强化公司经营管理，促使公司经营活动持续 健康发展，根据《中华人民共和国公司法》 《上海证券交易所股票上市规则》 《审 计署关于内部审计工作的规定》 《企业内部控制基本规范》 第四条 本制度适用于公司及公司所有全资子公司和控股子公司（以下简称 "公司及子公司"）。 第二章 内部审计机构和职责 第五条 公司设立审计法务部，配备专职内部审计人员。 审计法务部是审计委员会监督指导下独立开展工作的内部审计机构，是审 计人员的日常办事机构，依照国家法规、政策和企业规章制度，独立行使内部审 计职权 ...

Core Points - The document establishes a long-term mechanism to prevent major shareholders and related parties from occupying company funds and regulates financial transactions between the company and related parties [1][2] - The board of directors and senior management are obligated to ensure the safety of company funds and regulate financial transactions with related parties [1][2] Group 1: General Provisions - The provisions apply to the company and its wholly-owned and controlling subsidiaries regarding financial transactions with related parties [2] - The definition of fund occupation includes both operational and non-operational fund occupation [1][2] Group 2: Measures to Regulate Related Fund Transactions - The board of directors must review and approve the transaction amounts between the company and related parties, and take effective measures to stop any fund occupation [2][3] - Strict adherence to contract terms is required for operational fund transactions to avoid fund occupation [2][3] - The company is prohibited from providing funds to related parties in various specified ways, including covering expenses or lending funds without proper transaction backgrounds [2][3][4] Group 3: Responsibilities and Accountability - The board of directors must take immediate action to recover occupied funds and interest in cases of non-operational fund occupation [3][4] - Borrowing amounts over 3 million yuan that exceed 0.5% of the latest audited net assets requires board approval and disclosure [3][4] - The chairman of the board is the primary responsible person for preventing fund occupation and managing recovery efforts [4][5] Group 4: Accountability and Penalties - Directors and senior management who assist or condone fund occupation may face disciplinary actions, including potential dismissal [6] - In cases of violations, the company can impose administrative and economic penalties and may pursue legal responsibility against relevant individuals [6]

第一章 总则 第一条 为规范鲁商福瑞达医药股份有限公司（以下简称"公司"）信息披 露行为，加强信息披露事务管理，保护投资者合法权益，根据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《上海证券 交易所股票上市规则》（以下简称"《上市规则》"）、《上海证券交易所上市 公司自律监管指引第 2 号——信息披露事务管理》等国家有关法律、法规、规范 性文件及《鲁商福瑞达医药股份有限公司章程》（以下简称"公司章程"）的有 关规定，制定本信息披露管理制度（以下简称"本制度"）。 第二条 本制度所称"信息"是指所有可能对公司证券及其衍生品种交易价 格以及投资者作出价值判断和投资决策产生重大影响的信息，以及证券监督管理 部门要求披露的信息；信息披露文件主要包括定期报告、临时报告、招股说明书、 募集说明书、上市公告书、收购报告书等。 第三条 本制度所称"披露"是指在法律法规和中国证券监督管理委员会（以 下简称"中国证监会"）及上海证券交易所规定的时间内，在上海证券交易所的 网站和符合中国证监会规定条件的媒体上，以规定的披露方式向社会公众公布前 述信息，并按规定报送证券监管部门。 信息披露义务人，是 ...

General Provisions - The company establishes these rules to enhance management efficiency and scientific management levels in accordance with relevant laws and regulations [2] - The rules outline the responsibilities and work division of the general manager and deputy general managers, as well as other senior management personnel [2][3] - The selection of senior management personnel should be conducted in an open and transparent manner [2] Managerial Structure - The company has a managerial structure consisting of one general manager, one financial officer, and several deputy general managers and assistants [3] - Changes in the managerial personnel must be approved by the board of directors [3] Responsibilities of the General Manager - The general manager is responsible for daily operations, implementing board resolutions, and reporting to the board [3][4] - The general manager has the authority to make decisions on asset and fund utilization for transactions below 10% of the company's audited net assets [4][5] Responsibilities of the Deputy General Manager and Assistants - The deputy general manager and assistants assist the general manager and are responsible for their respective areas of work [5] - They can propose meetings and recommend personnel changes within their scope of responsibility [5] Financial Officer's Responsibilities - The financial officer is responsible for daily financial operations, preparing financial reports, and ensuring timely disclosures [6] - They also oversee budget plans and provide financial analysis to improve operations [6] General Manager's Office Meetings - The general manager's office meetings are held to manage daily operations and coordinate departmental activities [6][7] - Decisions made in these meetings must fall within the authority granted by the board of directors [7][8] Accountability - The company has the right to penalize senior management who fail to meet performance standards, including salary reductions and potential dismissal [9] - Senior management may be held liable for damages caused by negligence or violations of laws and regulations [9] Implementation and Amendments - These rules take effect upon approval by the board of directors, and any amendments will also require board approval [9]

[注 1] 呼吸系统用药的营业收入较上年同期减少 44.69%，主要系本报告 期急支糖浆、鼻窦炎口服液、散列通等销售额减少所致。 证券代码：600129 证券简称：太极集团 公告编号：2025-063 重庆太极实业（集团）股份有限公司 关于公司 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》 之《第六号—医药制造》的相关规定，现将公司 2025 年半年度主要经营数据 披露如下： | | | | | | | | | 单位：万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 行业 | 主营业务收入 2025 年 | 2024 年 | 增长率% | 主营业务成本 2025 年 | 2024 年 | 增长率% | 毛利率% 2025 年 | 2024 年 | 同比增长 百分点 | | | 1-6 月 | 1-6 月 | | 1-6 月 | ...

福瑞达公告，2025年上半年营业收入17.9亿元，同比下降7.05%。净利润1.08亿元，同比下降15.16%。 ...